Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics
(NQ:
SGMO
)
0.8444
-0.0156 (-1.81%)
Streaming Delayed Price
Updated: 12:19 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics
< Previous
1
2
3
4
5
6
Next >
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
February 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
February 21, 2023
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.
Via
MarketBeat
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 21, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
February 10, 2023
These cutting-edge biotech companies quickly fell out of favor with investors this week.
Via
The Motley Fool
Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile
August 30, 2022
Via
Benzinga
Earnings Scheduled For February 22, 2023
February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Via
Benzinga
Earnings Preview For Sangamo Therapeutics
February 21, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
December 28, 2022
On Wednesday, 258 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
December 21, 2022
On Wednesday, 152 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 22, 2022
Thursday's session saw 329 companies set new 52-week lows.
Via
Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
November 29, 2022
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group,
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 03, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics's Earnings Outlook
November 02, 2022
Sangamo Therapeutics (NASDAQ:SGMO) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
October 27, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate
October 12, 2022
Via
Benzinga
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
October 12, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold
September 23, 2022
Via
Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
September 20, 2022
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a...
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
August 30, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics's Return On Capital Employed Insights
August 22, 2022
According to data from Benzinga Pro, during Q2, Sangamo Therapeutics's (NASDAQ:SGMO) reported sales totaled $29.38 million. Despite a 1.83% increase in earnings, the company posted a loss of $43.17...
Via
Benzinga
Recap: Sangamo Therapeutics Q2 Earnings
August 04, 2022
Sangamo Therapeutics (NASDAQ:SGMO) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 04, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
July 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
July 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 19, 2022
Gainers Talis Biomedical (NASDAQ:TLIS) shares moved upwards by 10.6% to $0.94 during Tuesday's after-market session. The company's market cap stands at $25.0 million.
Via
Benzinga
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
June 01, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
May 25, 2022
On Wednesday, 215 companies set new 52-week lows.
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 05, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.